Can AI Revolutionize Blood Cell Analysis? Tencent and Mindray’s New Partnership

Tencent AI Lab announced a partnership with Shenzhen Mindray to jointly develop an AI-powered blood cell analysis product.

Why Blood Cell Analysis Matters

Blood cell analysis, commonly known as a routine blood test, provides critical information for diagnosing a wide range of conditions, including infectious diseases such as pneumonia and hematologic disorders like leukemia.

In China, leukemia incidence is 2.76 per 100,000, ranking among the top ten causes of cancer death; early detection through blood screening can dramatically improve survival rates.

Challenges in Traditional Microscopy

The morphological examination of blood smears requires highly experienced physicians, is time‑consuming, and suffers from a talent shortage, leading to a “generation gap” in microscopy expertise.

Hospitals face exponential growth in sample volume, yet the limited number of skilled technicians results in low adoption rates of morphology testing, increasing the risk of missed diagnoses.

AI‑Powered Automated Analyzer

Tencent AI Lab applies advanced AI techniques—Auto‑ML, Auto‑Augmentation, Neural Architecture Search, and multi‑agent decision systems—to create an automated analyzer that can detect cell quality changes, achieve world‑leading cell recognition accuracy, and offer a cost‑effective alternative to expensive foreign equipment.

Detects changes in cell quality

World‑leading cell identification performance

Lower cost compared with high‑priced overseas products

The system also incorporates model compression and computational graph simplification to enhance efficiency and reduce hardware requirements.

Collaboration Highlights

Yang Wei, General Manager of Tencent AI Lab, emphasized that “AI + medical/healthcare” is a core long‑term research direction, and the partnership aims to assist doctors and serve patients.

Qian Tianyi, General Manager of Tencent Miyi, highlighted the open medical‑AI platform that provides algorithm, data, and management services to the industry.

Yan Huawen, General Manager of Mindray’s In‑vitro Diagnostics Division, noted that the joint effort will greatly enhance intelligent detection capabilities in clinical settings.

Future Outlook

The collaboration will explore AI applications in other in‑vitro diagnostics such as urine analysis, smart laboratories, and large‑scale diagnostic data, driving advancements in medical technology worldwide.